



ADULT MEDICATION GUIDELINE

ROPIVACAINE

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

[HIGH RISK Medication](#) 

Medication Class

Local Anaesthetics

Presentation

Form:

Ampoule: 0.2% (20mg/10mL)

Ampoule: 0.75% (75mg/10mL)

Ampoule: 1% (200mg/20mL)

Bag: 0.2% (400mg/200mL)

Combination Product:

Bag: 0.2% with Fentanyl 4microg/mL (200mL)*

*Formulary: Restricted and Schedule 8 Medication for combination with fentanyl

Storage

Store at room temperature, below 25°

Dose

Epidural Analgesia:

The dose used varies depending on factors such as the area to be anaesthetised, vascularity of tissues, number of neuronal segments to be blocked, individual tolerance and techniques used. Consult anaesthetist.

Ropivacaine 0.2% at dosage rates of 4-12mL/hr is often one of the medications used with pethidine or fentanyl initially in the epidural infusion.

Rectus Sheath Catheter:

10 – 20 mL of Ropivacaine 2mg/mL (0.2%) via each catheter should be prescribed regularly, 6 hourly, for the first 72 hours. The volume of local anaesthetic prescribed is dependent upon patient weight: e.g. 40-50kg 10mL, 50-60kg 15mL and >70kg 20 mL 6 hourly.

Consult anaesthetist for further information.

Contraindications:

IV Injection, IV Infusion

Administration

Refer to the [Australian Injectable Drugs Handbook](#)

Epidural Infusion or Rectus Sheath Catheter

Dilute with sodium chloride 0.9% injection when concentrations lower than those available commercially are required.

Monitoring

Monitor blood pressure, heart rate, and vital signs during administration.

Pregnancy

1st Trimester: Considered safe to use

2nd Trimester: Considered safe to use

3rd Trimester: Considered safe to use

Breastfeeding

Safe to use

Comments

IV injection or infusion of ropivacaine is contraindicated

Related Policies, Procedures & Guidelines

NMHS Governance Procedures:

[Destruction, Discard and Disposal of Schedule 8 \(S8\) and Schedule 4 Restricted \(S4R\) Medicines](#)

WNHS Clinical Practice Guidelines:

[Postoperative Management: Anaesthetics](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[High Risk Medications](#)

[Return & Disposal of Medications](#)

References









Australian Medicines Handbook. Ropivacaine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Sept 24]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Ropivacaine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 21 Sept 24]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Ropivacaine hydrochloride. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Sept 24]. Available from: <http://aidh.hcn.com.au>

MIMS Australia. Ropivacaine Kabi. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 20121 [cited 2021 Sept 24]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. Naropin with fentanyl. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 Sept 24]. Available from: <https://www.mimsonline.com.au>

Keywords	Ropivacaine, epidural, rectus sheath catheter, analgesia, postoperative				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	June 2015	Last Reviewed:	24/09/2021	Review Date:	Nov 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	02/11/2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.